|
font size Sign in
The American Society of Clinical Oncology’s ASCO 2013 Annual Meeting kicks off in Chicago May 31. Though the meeting attracts cancer researchers and physicians from around the world, it is closely watched by Wall Street for news of clinical trial results that could send stocks soaring or sinking. We spoke to Adam Feuerstein, senior columnist for TheStreet.com, about a new class of cancer therapies likely to get big attention at this year’s meeting, what other news will be coming out of the conference, and whether concerns about payers willingness to continue meeting the high price commanded by new cancer therapies becomes a topic of discussion in Chicago. Read More ![]()
Innovation
Deals
Stem Cells
Court Rulings
Mental Health
Dealmaking
Business Models
Medical Devices
Obesity
Business Strategy
![]()
White Paper
Reducing Readmissions in Europe
Now Available
The Burrill Report May 2013
Podcast
What Transparency Means for Healthcare
Allen Frances, professor emeritus at Duke University and chairman of the DSM IV task force, discusses his criticism of the American Psychiatric Association's fifth edition of its Diagnostic and Statistical Manual of Mental Disorders, or DSM-5, the damage he fears it will cause, and what he calls “the medicalization of normal.”
Burrill Report Data Center
Capital Scorecard
By the numbers
Life Sciences IPOs Accelerate
|